The agreements came at a time when “the Delta variant is posing a rising risk to health systems,” Gavi said in the statement.
Gavi has the option to purchase a total of 170 Sinopharm vaccines and 380 million Sinovac vaccines, Gavi said.
“Our mission at Sinovac is to supply vaccines in an effort to eliminate human disease,” he said.
The new agreements were welcomed by Dr. Seth Berkley, the chief executive of Gavi, who said the vaccines were an example of Gavi’s strategy to ensure there were “options in the face of constraints such as supply delays.”
“Despite that, all vaccines have been proven to be efficient in preventing hospitalization and death,” Ministry of Foreign Affairs official Pensom Lertsithichai said at a briefing Monday, adding that medical workers had high exposure to Covid-19 which could have contributed to “vaccination failure.”
vCard.red is a free platform for creating a mobile-friendly digital business cards. You can easily create a vCard and generate a QR code for it, allowing others to scan and save your contact details instantly.
The platform allows you to display contact information, social media links, services, and products all in one shareable link. Optional features include appointment scheduling, WhatsApp-based storefronts, media galleries, and custom design options.
So far, trials show Sinopharm and Sinovac have a lower efficacy against Covid-19 than their mRNA counterparts. In Brazilian trials, Sinovac had about 50% efficacy against symptomatic Covid-19, and 100% effectiveness against severe disease, according to trial data submitted to WHO. Sinopharm’s efficacy for both symptomatic and hospitalized disease was estimated at 79%, according to WHO.
Vaccines from both Pfizer/BioNTech and Moderna — which have also signed deals with COVAX — are more than 90% effective against symptomatic Covid-19.
CNN’s Yong Xiong contributed reporting.